Core Viewpoint - The A-share market shows strong momentum entering 2026, with the pharmaceutical sector rebounding significantly, as evidenced by the 7.81% increase in the pharmaceutical and biotechnology index in just five trading days [1][23]. Group 1: Fund Performance - The E Fund Healthcare Fund has outperformed the industry index with a net value increase of 16.85% in the same period [1][23]. - Since manager Yang Zhenshao took over in August 2016, the fund has achieved a return of 237.49% and an annualized return of 13.81% [1][23]. - The fund has consistently outperformed the pharmaceutical and biotechnology index for nine consecutive years since 2017, demonstrating the manager's value [1][23]. Group 2: Investment Strategy - Yang Zhenshao's investment approach combines macro and micro perspectives, focusing on industry cycle positions and trends while pursuing long-term alpha through bottom-up balanced allocation [26][30]. - The fund maintains a high stock position, typically over 92%, with a relatively low turnover rate, indicating a long-term investment style [27][28]. - The strategy emphasizes the importance of deep research to support long-term holdings, which helps avoid excessive trading and capitalizes on systematic industry growth opportunities [28][30]. Group 3: Market Trends and Opportunities - Yang Zhenshao is keenly aware of new industry trends, having positioned the fund in advance of the recent surge in innovative drugs, which has contributed to the fund's strong performance [30][34]. - The pharmaceutical index has shown a significant long-term growth of 1090.57% over the past 20 years, far exceeding the 401.52% growth of the CSI 300 index [30][31]. - The current focus is on the innovative drug sector, which is expected to recover in liquidity, providing attractive opportunities for quality asset allocation [40][42]. Group 4: Future Outlook - The strategy remains to pursue stable excess returns while dynamically adjusting allocation ratios based on the economic conditions of various pharmaceutical sub-sectors [39][40]. - The launch of the new E Fund Hong Kong Stock Connect Healthcare Mixed Fund aims to capture the global benefits of China's pharmaceutical innovation [43][44]. - Yang Zhenshao's proven track record and deep research background position him as a valuable asset in navigating the evolving pharmaceutical investment landscape [44].

Core Viewpoint - The article highlights the strong performance of overseas stock indices and the corresponding success of QDII funds, particularly those investing in the Hong Kong and US markets, with a focus on healthcare and technology sectors [3][4][8]. Group 1: Overseas Stock Market Performance - Multiple overseas stock indices, including NASDAQ, S&P 500, and DAX, reached historical highs in July 2025, with many indices showing over 20% gains in the first half of the year [3][4]. - The DAX index recorded a 31.12% increase over the past year and an 87.03% increase over three years, while the NASDAQ and S&P 500 also showed significant gains [5][6]. Group 2: QDII Fund Overview - QDII funds, which allow domestic investors to invest in overseas markets, primarily target Hong Kong and the US, with some exposure to emerging markets like Vietnam and India [7][8]. - As of June 30, 2025, there were 525 equity QDII funds, accounting for 77.43% of total QDII funds, with a total scale of approximately 682.8 billion yuan [8]. Group 3: QDII Fund Performance - The average return for equity QDII funds in the first half of 2025 was approximately 13.46%, with a median return of 9.72%. Over three years, the average return was about 36.21% [9][10]. - The top 20 equity QDII funds in the first half of 2025 had a return threshold close to 32%, outperforming major global indices, with a significant portion invested in Hong Kong's innovative pharmaceutical sector [10][11]. Group 4: Top Performing QDII Funds - The top three performing QDII funds for the first half of 2025 were: 1. Huatai-PineBridge Hong Kong Advantage Selection Mixed (QDII) A 2. E Fund Global Pharmaceutical Industry Mixed (QDII) A 3. ICBC New Economy Mixed (QDII) RMB [11][18]. - The Huatai-PineBridge fund achieved a return of approximately 86.48% in the first half of 2025, with a one-year return of 92.59% [14][19]. Group 5: Sector Focus - The article emphasizes that a significant number of top-performing QDII funds are heavily invested in the healthcare sector, particularly in innovative pharmaceutical companies listed in Hong Kong [15][22]. - The top-performing funds over the past year also included those with substantial holdings in technology giants and new consumer companies [22][28].